0
Obstructive Lung Diseases |

Chronic Obstructive Pulmonary Disease: Diagnosis and Treatment Guidelines of the Czech Pneumological and Phthisiological Society (CPPS)

Vladimir Koblizek, MD; Jan Chlumsky, MD; Vladimir Zindr, MD; Vratislav Sedlak, MD; Jana Satinska, MD; Katerina Neumannova, DrPH; Sarka Pracharova, MD; Jaromir Zatloukal, MD
Author and Funding Information

University Hospital, Hradec Kralove, Czech Republic


Chest. 2013;144(4_MeetingAbstracts):696A. doi:10.1378/chest.1703297
Text Size: A A A
Published online

Abstract

SESSION TITLE: COPD Diagnosis & Evaluation Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: COPD is a global phenomenon.Currently in the world there are several parallel,not entirely compatible,medical statements and strategies.The authors aim to present new phenotypically tailored guideline.

METHODS: CPPS commissioned an Expert group to draft the recommended guideline for diagnosis and treatment of stable COPD. Subsequent revisions led to a version discussed at the National Consensus Conference(NCC). Reviewers comments and results of the NCC enabled this final version of the document to be created.

RESULTS: The hallmark of the modern approach to COPD is a view of the patient through the prism of lung function, symptoms, occurrence of exacerbations and clinical phenotypes. CPPS identifies six relevant phenotypes: frequent exacerbator, COPD-asthma overlap, COPD - bronchiectasis overlap, emphysematic phenotype , bronchitic phenotype and pulmonary cachexia phenotype. Treatment recommendations can be divided into four steps. 1st step=Risk exposure elimination: ↓smoking and ETS, ↓home and occupational risks. 2nd step=Essential treatment: inhaled bronchodilators, regular physical activity, pulmonary rehabilitation, education, inhalation training, comorbidity treatment, vaccinations. 3rd step=Phenotypically targeted treatment: PDE4i, ICS+LABA,LVRS, BVR, AAT augmentation, physiotherapy, mucolytic, ATB. 4th step=Care for respiratory insufficiency and terminal COPD: LTOT, lung transplantation,high intenstity-NIV and palliative care.

CONCLUSIONS: Optimal treatment of COPD patients requires individualized and multidisciplinary approach to the patient's symptoms, clinical phenotypes, needs and wishes . New Czech COPD guideline reflects these requirements.Supported by MH CZ-DRO(FNHK).

CLINICAL IMPLICATIONS: Czech guideline offers personalised approach to care in the field of COPD reflecting the symptoms and phenotypes of each patient.

DISCLOSURE: Vladimir Koblizek: University grant monies: Czech National Register of COPD - consultant fees, Consultant fee, speaker bureau, advisory committee, etc.: Boehringer Ingelheim, Consultant fee, speaker bureau, advisory committee, etc.: Glaxo, Consultant fee, speaker bureau, advisory committee, etc.: Novartis, Consultant fee, speaker bureau, advisory committee, etc.: Takeda , Consultant fee, speaker bureau, advisory committee, etc.: Astra Zeneca Vladimir Zindr: Consultant fee, speaker bureau, advisory committee, etc.: Boehringer, Consultant fee, speaker bureau, advisory committee, etc.: Glaxo Vratislav Sedlak: University grant monies: Masaryk University Brno, Consultant fee, speaker bureau, advisory committee, etc.: Boehringer Ingelheim , Consultant fee, speaker bureau, advisory committee, etc.: Novartis , Consultant fee, speaker bureau, advisory committee, etc.: Glaxo Jana Satinska: Consultant fee, speaker bureau, advisory committee, etc.: Boehringer Ingelheim, Consultant fee, speaker bureau, advisory committee, etc.: Takeda , Consultant fee, speaker bureau, advisory committee, etc.: Novartis , Consultant fee, speaker bureau, advisory committee, etc.: Astra Katerina Neumannova: Consultant fee, speaker bureau, advisory committee, etc.: Respironic Jaromir Zatloukal: Consultant fee, speaker bureau, advisory committee, etc.: Novartis , Consultant fee, speaker bureau, advisory committee, etc.: Beohringer Ingelheim , Consultant fee, speaker bureau, advisory committee, etc.: Astra The following authors have nothing to disclose: Jan Chlumsky, Sarka Pracharova

No Product/Research Disclosure Information


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543